Oxy Watchdog

Keeping An Eye On OxyContin

Posts Tagged ‘pharmaceutical’

New brand of prescription painkiller oxycodone approved

Posted by Oxy Watchdog on October 23, 2010

A new form of oxycodone hydrochloride, a synthetic opiate like the brand name drug OxyContin, was approved by the U.S. Food and Drug Administration this week, reports this release from the FDA. Lehigh Valley Technologies formulated the brand-name Oxycodone HCI as a morphine-derived painkiller to rival Purdue Pharma’s best-selling brand OxyContin. Purdue has tried to limit production of time-release and generic brands of oxycodone and has been embroiled in several lawsuits to maintain control of its $3 billion-per-year drug. According to its website, Lehigh Valley has developed its own version of abuse-deterrent drugs. In 2009, Lehigh Valley received a warning from the FDA for marketing an unapproved version of morphine, as detailed in this letter from the FDA. Like the brand-name OxyContin, Oxycodone HCI is a Schedule II narcotic and highly prone to addiction.

Read more about Purdue’s suppression of generic forms of oxycodone here.

Posted in Pharmaceutical Industry | Tagged: , , , , , , , , , , , , , , , , , | Leave a Comment »

Makers of Oxy contribute to prescription monitoring programs

Posted by Oxy Watchdog on October 22, 2010

Purdue Pharma, makers of OxyContin, contributed $200,000 towards the support and implementation of prescription drug monitoring programs earlier this week, according to this article from News-Medical.net. The monies were contributed to the non-profit National Association of State Controlled Substances Authorities and will go toward grants which assist states to maintain prescription monitoring programs, the Association’s main focus. In the article, a Purdue representative states that the pharmaceutical company has been supporting appropriately-designed monitoring programs to help reduce the abuse and diversion of prescription drugs. According to the article, the Association will manage the funding of grants and Purdue will have no input in the final selection process. Though OxyContin abuse has skyrocketed in the U.S. and abroad, Purdue Pharma makes a reported $3 billion per year on the opiate painkiller.

Read more about prescription monitoring programs here.

Posted in Pharmaceutical Industry | Tagged: , , , , , , , , , , , , , , | 1 Comment »

Prescription Take-Back Day yields 121 tons of drugs

Posted by Oxy Watchdog on October 17, 2010

The U.S. Drug Enforcement Agency pronounced Prescription Drug Take-Back Day a success after results of the first-ever national initiative were tallied earlier this month. According to this press release from the DEA, more than 242,000 pounds of prescription drugs were collected at over 4,000 take-back sites across the country. Though the Secure and Responsible Drug Disposal Act signed into law earlier this week makes returning unused prescription drugs more feasible, the DEA plans to keep Sept. 25 designated as Prescription Drug Take-Back Day until more permanent measures are in place.

Read more on the Secure and Responsible Drug Disposal Act here.

Find more information on the DEA’s National Take-Back Day here.

Posted in Policy & Regulation | Tagged: , , , , , , , , , , | Leave a Comment »

Prescription drug disposal bill signed into law

Posted by Oxy Watchdog on October 16, 2010

Earlier this week, President Barack Obama signed into law a bill that amends the Controlled Substances Act, reports the Community Anti-Drug Coalitions of America here. The Secure and Responsible Drug Disposal Act is intended to correct a provision in the original statute that requires drugs to be registered with the U.S. Drug Enforcement Agency before they will be accepted for proper disposal. It also increases sentencing guidelines for entities that instead of properly disposing drugs returned to them, use them in illegal activities. Though the bill as approved by the U.S. House of Representatives included a provision for a study by the U.S. Environmental Protection Agency on the effects of the drugs on waterways, the final version nixed that portion, reports the Association of California Waterways in this release. The bill was originally passed by the House and Senate in early August and late September respectively, on the heels of the creation of the first ever National Prescription Drug Take-Back Day Sept. 25th by the DEA.

Read more about the Act, National Prescription Drug Take-Back Day, and the effects of drugs on waterways and the Controlled Substance here.

Posted in Informational, Policy & Regulation | Tagged: , , , , , , , | 1 Comment »

Pfizer snaps up maker of less-abusable OxyContin

Posted by Oxy Watchdog on October 12, 2010

King Pharmaceuticals, the maker of oxycodone-containing painkillers Remoxy and Acurox, has been bought by Pfizer for $3.6 billion, according to this article in the Washington Post. Remoxy was designed to be an abuse-resistant, control-released form of the opioid painkiller OxyContin, but was rejected by the U.S. Food and Drug Administration in 2008, reports this article from The Street. King also developed Acurox, another abuse-resistant opioid painkiller set to be submitted to the FDA in 2011. According to the Washington Post, with Pfizer at the helm, sales of the drugs could reach $500 million per year. Purdue Pharma, makers of OxyContin, are also developing a less-abusable version of their $3 billion per-year painkiller.

Read about Purdue’s less-abusable version of OxyContin here.

Posted in Pharmaceutical Industry | Tagged: , , , , , , , , , , , , , , | Leave a Comment »

New opioid painkiller may rival OxyContin in the marketplace

Posted by Oxy Watchdog on September 30, 2010

As the pharmaceutical companies Grunenthal and Johnson & Johnson release positive final-stage trial results for their new opioid painkiller tapentadol extended-release, market predictors estimate the new drug will rival or possibly even replace OxyContin as the top medication for chronic pain. According to this article in Trading Markets.com, Datamonitor forecasts sales to reach over $800 million by 2019. If approved for sale in the U.S., tapentadol will be the first new opioid to reach the marketplace in over 25 years. As an opioid-based, Schedule II drug like OxyContin, tapentadol may also become highly addictive and should be used under careful supervision, states Johnson & Johnson in this press release.

Posted in Pharmaceutical Industry | Tagged: , , , , , , , , , , , | 1 Comment »

DEA launches first-ever Prescription Drug Take-Back Day

Posted by Oxy Watchdog on September 20, 2010

In response to the nation’s growing prescription drug abuse problem, the Drug Enforcement Administration is sponsoring the first-ever National Prescription Drug Take-Back Day this Saturday, Sept. 25. Government, community, public health and law enforcement partners will be collecting expired, unused, and unwanted prescription drugs for destruction at sites across the nation from 10 a.m. to 2 p.m. local time. The service is free and anonymous, no questions asked.

Watch Joanne Peterson of Learn To Cope weigh in on the event here, and read more about the DEA’s campaign here.

Find a collection site near you here.

Posted in Policy & Regulation | Tagged: , , , , , , , , , , , , , , , , , | 3 Comments »

Purdue to pay $16 million for suppressing generic brands of OxyContin

Posted by Oxy Watchdog on September 8, 2010

Purdue Pharma, manufacturer of prescription pain pill OxyContin, will pay $16 million to direct purchasers of the drug who claim Purdue obtained patents through misleading information, according to this article in the Wall Street Journal. Since the patents were filed in the 1990s, purchasers of the drug accused the pharmaceutical company of using invalid patents to sue companies making generic versions of OxyContin, thereby delaying the FDA approval process for those generics, reports Law 360. Purdue has already settled the majority of 57 similar cases.

Read about other cases against Purdue from makers of generic OxyContin here.

Posted in Litigation, Pharmaceutical Industry | Tagged: , , , | 1 Comment »

 
%d bloggers like this: